Opendata, web and dolomites

IPUD SIGNED

An Implantable Peritoneal Ultrafiltration Device that actively and continuously prevents fluid overload in congestive heart failure patients

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 IPUD project word cloud

Explore the words cloud of the IPUD project. It provides you a very rough idea of what is the project "IPUD" about.

minimally    chf    efficacy    healthcare    resistant    carry    thanks    eliminates    safety    overload    diuresis    dialysis    prevent    accumulates    health    recurrence    instability    validation    treatments    patient    catheter    pathologic    perform    accumulation    ultrafiltration    clinical    intravenous    heart    shock    device    direct    26    systemic    physicians    function    severe    worsening    eliminating    complications    chronic    life    frequent    treatment    preventing    aggressive    hospitalizations    continuous    million    billion    reduce    worldwide    congestion    patients    pump    laparoscopic    fluid    renal    removal    24    diuretic    metabolic    isotonic    drains    monitoring    solutions    ipud    water    global    paragate    sensing    therapy    preclinical    volume    slowly    people    validate    body    fluids    extracellular    pilot    urinary    platform    implantable    quality    peritoneal    infusion    verification    moderate    absorbs    arrhythmia    congestive    invasive    recurred    significantly    guarantees    hemodynamic    medical    trial    acute   

Project "IPUD" data sheet

The following table provides information about the project.

Coordinator
PARAGATE MEDICAL LTD 

Organization address
address: 13 WADI EL HADJ
city: NAZARETH
postcode: n.a.
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Total cost 2˙909˙785 €
 EC max contribution 2˙036˙849 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-08-01   to  2021-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    PARAGATE MEDICAL LTD IL (NAZARETH) coordinator 2˙036˙849.00

Map

 Project objective

Pathologic fluid overload (congestion) is a medical condition when high volume of fluid (water) accumulates in the body leading to congestive heart failure (CHF). CHF is a severe global health problem affecting each year ~26 million people worldwide, of which 8 million are chronic and diuretic resistant patients. Current solutions for fluid overload in diuretic resistant patients such as infusion pump for intravenous (IV) diuresis, catheter-based device for ultrafiltration therapy and peritoneal dialysis all carry complications and are acute treatments which do not prevent recurrence. Paragate developed IPUD a unique implantable peritoneal ultrafiltration system for continuous monitoring and removal of extracellular fluids in CHF patients. It is minimally invasive (laparoscopic approach) and continuously (24/7) and slowly absorbs systemic isotonic extracellular fluid and drains it to the urinary system preventing recurred accumulation. In addition, IPUD guarantees a continuous monitoring of the fluid as well as the urinary system function thanks to a sensing system (embedded into the implantable system) and a treatment management platform. In this way, physicians have a direct control of the treatment and patient’s condition. The controlled, moderate non-aggressive fluid removal eliminates the main complications associated with the acute and aggressive treatments that lead to hemodynamic shock, worsening of renal function, arrhythmia and metabolic instability. Thanks to IPUD, patients will improve their quality of life eliminating frequent hospitalizations with a more effective treatment and healthcare systems will significantly reduce the €100 billion/year cost for frequent hospitalizations and treatment costs. The Phase 2 project will enable Paragate to scale-up production, perform validation and verification activities including a preclinical study; and validate the safety and efficacy of IPUD in a pilot clinical trial.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IPUD" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "IPUD" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DetectInMen (2019)

Infection detection in human semen

Read More  

ADAPTOS (2019)

ADAPTOS - Changing the way bone voids are treated

Read More  

Savesight (2020)

Contact lens embedded sensor for ocular hypertension and glaucoma monitoring

Read More